CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ, Dominika ŠKRNOVÁ, Václav HEJRET and Michal ŠMÍDA. CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia. In PhD and PostDoc RETREAT, Sněžné, Milovy. 2023.

Basic information

• Original name: CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.
• Authors: PESCHELOVÁ, Helena (203 Czech Republic, belonging to the institution), Veronika KOZLOVÁ (203 Czech Republic, belonging to the institution), Veronika MANČÍKOVÁ (703 Slovakia, belonging to the institution), Lenka DOSTÁLOVÁ (203 Czech Republic, belonging to the institution), Adriana LADUNGOVÁ (703 Slovakia, belonging to the institution), Dominika ŠKRNOVÁ (203 Czech Republic, belonging to the institution), Václav HEJRET (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, guarantor, belonging to the institution).
• Edition: PhD and PostDoc RETREAT, Sněžné, Milovy, 2023.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30204 Oncology
• Country of publisher: Czech Republic
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• RIV identification code: RIV/00216224:14740/23:00132849
• Organization unit: Central European Institute of Technology
• Keywords in English: Chronic lymphocytic leukemia; somatic mutations; CRISPR/Cas9 screening
• Tags: rivok
• Tags: Reviewed

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by genetic heterogeneity and a variety of somatic mutations, the most frequent of which targeting ATM, TP53, NOTCH1, MYD88 and SF3B1 genes. A thorough exploration of these mutations could shed light on the disease etiology, or even lead to the discovery of potential novel drug targets. However, CLL cells extracted from patients do not proliferate ex vivo and thus preclude lengthy experiments, such as CRISPR/Cas9 screening. 76 The aim of this study was to generate stable knockout (ATM, TP53) and knock-in (NOTCH1, SF3B1 and MYD88) CLL cell lines and subsequently use them to investigate unique vulnerabilities specific to these mutations

Links

• LX22NPO5102, research and development project: Name: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)

Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES

• MUNI/A/1224/2022, interní kód MU: Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X

Investor: Masaryk University